)
Measured by SNOT-22, a QoL questionnaire used for CRSwNP patients1
Analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be made.1
aWeek 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W +
INCS (n=150) and placebo + INCS (n=153): -10.57 (95% CI: -14.47,
-6.66) (-18.97 from a
baseline score of
50.16 vs -8.40 from a baseline score of 53.48,
respectively).1
bWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W
+ INCS (n=150) and placebo + INCS (n=153): -16.76 (95% CI:
-20.85, -12.67) (-27.08 from a
baseline score of
50.16 vs -10.32 from a baseline score of 53.48,
respectively).1
cWeek 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W
+ INCS (n=150) and placebo + INCS (n=153): -20.96 (95% CI:
-25.03, -16.89) (-29.84 from a
baseline score of
50.16 vs -8.88 from a baseline score of 53.48,
respectively).1
dWeek 24 (key secondary endpoint). LSM difference between
DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS
(n=153): -17.36 (95% CI: -20.87, -13.85)
(-27.77 from a baseline score of 51.02 vs -10.40 from a
baseline score of 53.48, respectively)
(P<0.0001).1
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.2
TURN TO DUPIXENT TO IMPROVE A RANGE OF CRSwNP SYMPTOMS
AND QoL MEASURES1
SNOT-22 MEASURES
THE QoL OF CRSwNP
PATIENTS1
The SNOT-22 score is calculated from a patient questionnaire in which 22 symptoms are rated from 0 (“no problem”) to 5 (“problem as
bad as it can be”) based on the severity and frequency of each particular item.2,3
The study was not designed to measure the impact of treatment on the individual components. Therefore, improvement in
the total aggregate SNOT-22 score does not necessarily correlate with a positive effect on each individual item or domain.3,4
Sleep
- Difficulty falling
asleep - Wake up at night
- Lack of a good
night's sleep
Function
- Wake up tired
- Fatigue
- Reduced
productivity - Reduced
concentration
Ear/Facial
- Ear fullness
- Dizziness
- Ear pain
- Facial pain/
pressure
Emotional
- Frustrated/
restless/irritable - Sad
- Embarrassed
Nasal
- Need to blow nose
- Nasal blockage
- Sneezing
- Runny nose
- Cough
- Postnasal discharge
- Thick nasal discharge
- Decreased sense of
smell/taste
22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0-110); reduced score indicates improvement.2
INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks; QoL, quality of life.